CompletedPhase 2ACTRN12606000040561

The safety and efficacy of Cpn10 in psoriasis

A single centre, double blind, parallel group, three arm, Phase IIa clinical trial designed to assess the efficacy and safety of Cpn10 administered as twice weekly intravenous injections in subjects with plaque psoriasis.

Sponsor

CBio Limited

Enrollment

24 participants

Start Date

Jul 1, 2005

Study Type

Interventional

Conditions

Psoriasis

Summary

Safety and effectiveness of Cpn10 in patients with moderate to severe psoriasis. Three doses of Cpn10 are being trialed. The study personnel performing the assessments, the sponsor and the patient are blinded to which of the three doses are administered.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 75 Yearss

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying The safety and efficacy of Cpn10 in psoriasis. You may be eligible if you are people aged 18 to 75. Participation typically involves medical assessments, possible treatment with the study intervention, and follow-up visits to track your health.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Cpn10 7.5mg twice per week Cpn10 10mg twice per week given as intravenous injections over 12 weeks

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12606000040561

Related Trials

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT0381634552 locations

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

NCT0685794243 locations

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT074492341 location

A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis

NCT075324861 location

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

NCT048648861 location